{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.8","upperLimit":"89.1","value":"63.6"},{"groupId":"OG001","lowerLimit":"19.4","upperLimit":"99.4","value":"75.0"},{"groupId":"OG002","lowerLimit":"28.4","upperLimit":"99.5","value":"80.0"},{"groupId":"OG003","lowerLimit":"26.8","upperLimit":"69.4","value":"47.8"},{"groupId":"OG004","lowerLimit":"29.0","upperLimit":"96.3","value":"71.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"7"}],"units":"Participants"}],"description":"The CBR was the proportion of participants who have achieved a CR, PR or SD assessed at least 28 days after first dose date of study drug. For participants with clinically and/or radiologically evident EBV LPD or malignancies, CR as complete resolution of all clinical and radiologic evidence of lymphoma, confirmed by biopsy of affected tissues when indicated, lasting for at least 3 weeks following completion of a cycle of tabelecleucel or EBVCTLs; and a PR as a \\>= 50% reduction in size of all lymphomatous lesions as determined by CT or MRI scan measurements of tumor volume, maintained for at least 3 weeks following completion of a cycle of tabelecleucel or EBV-CTLs. For participants without clinically and/or radiologically evident tumors with increasing levels of EBV DNA, CR as clearance of EBV without subsequent development of EBV+ LPD; and PR as at least a 10-fold decrease in EBV DNA levels. The CBR was included specifically as clinically meaningful for solid tumor, namely LMS.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with EBV+ PTLD following HCT who were R/R to rituximab received IV infusion of tabelecleucel on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"EBV+ PTLD-HCT R/R Rituximab (Tab-cel Only)"},{"description":"Participants with EBV+PTLD following SOT who were R/R to rituximab and chemotherapy received IV infusion of tabelecleucel on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"EBV+ PTLD-SOT R/R Rituximab + Chemo (Tab-cel Only)"},{"description":"Participants with EBV+ following LMS received IV infusion of tabelecleucel on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"EBV+ LMS (Tab-cel Only)"},{"description":"Participants with EBV+PTLD following HCT who were R/R to rituximab or rituximab naive received donor-derived EBV-CTL on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.","id":"OG003","title":"EBV+ PTLD-HCT R/R Rituximab (EBV-CTLs Only)"},{"description":"Participants with EBV+ following viremia received donor-derived EBV-CTLs on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.","id":"OG004","title":"EBV+ Viremia (EBV-CTLs Only)"}],"paramType":"NUMBER","populationDescription":"Full analysis set included all participants who received at least one dose of study treatment (tabelecleucel or EBV-CTLs). Participants who achieved CR, PR or SD were analyzed for this outcome measure. Results from arms with \\<= 3 participants (as shown in the participant flow) are excluded due to the low numbers of participants; these low numbers pose a risk for participant re-identification in these rare indications of this single center study.","reportingStatus":"POSTED","timeFrame":"From Day 1 through 251.1 months after Day 1 dose","title":"Clinical Benefit Rate (CBR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}